Trialwise, Inc. is proud to be a CRO partner of SRI International in developing an oral treatment for radioactive poisoning. SRI International has engaged Trialwise to provide clinical operations, data management...

Trialwise Supports SRI International Phase 1 Study

Developing a Treatment for Radioactive Poisoning

August 16, 2023

Results from an early phase study supported by Trialwise indicate that an ophthalmic emulsion developed by Skye Bioscience as a potential treatment for glaucoma has been well-tolerated in healthy volunteers.

Ophthalmic Emulsion Early-Stage Data Released

Skye Bioscience’s SBI-100 Ophthalmic Emulsion Glaucoma Treatment Candidate Well Tolerated by Healthy Volunteers in Phase 1 Clinical Trial Supported by Trialwise

November 6, 2023

Press Releases